ProCE Banner Activity

B-Cell Lymphomas: A European Perspective on Key Trials From ASH 2020

Conference Coverage
Multimedia
Watch this focused video featuring an EU expert’s perspective on the clinical implications of key data on CLL and MCL from ASH 2020.

Released: March 17, 2021

Expiration: March 16, 2022

No longer available for credit.

Share

Faculty

Lydia Scarfò

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Target Audience

This program is intended for ex-US physicians and other healthcare professionals who care for patients with hematologic malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate clinical trial data of current hematologic malignancies and determine how they have an impact on evolving clinical practice patterns as well as how these data can be applied to personalize care and optimize patient outcomes
  • Assess the mechanisms of action of novel investigational agents being examined in patients with hematologic malignancies, including leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma
  • Develop strategies to address treatment-related adverse events in patients who receive therapy for hematologic malignancies

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Lydia Scarfò, MD, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Gilead Sciences, and Janssen.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Program Medium

This program has been made available online.

Participation in this self-study activity should be completed in approximately hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 17, 2021, through March 16, 2022:

1. Register online at httpProgram Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with cancer.

Goal


The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with hematologic malignancies.